MESOX has just won the National Start-Up Award from Medilink UK, building upon the earlier regional win in the Midlands from Medilink Midlands in May this year.
The judges highlighted two compelling reasons for their choice:
MESOX’s work to develop advanced carrier technology with a mission to transform the development of pharmaceuticals, enhance bioavailability, and ultimately improve patient treatment.
The potential of the business to become a unique international research-based pharmaceutical company in the Midlands.
Our CEO and Founder, Dr. Ali Al-khattawi, described the win as a “proud moment for the MESOX team and a testament to the potential of our company. To be selected from among hundreds of great life science start-ups in the UK is a great privilege. This highlights the transformative potential of our company in advancing the formulation development of innovative therapeutics.”
The Medilink UK National Healthcare Business Awards showcase the best and brightest in the life science and healthcare technology sectors, recognizing companies that demonstrate exceptional innovation, commercial success, and patient impact.
MESOX’s win is a significant achievement, underscoring the company’s dedication to advancing healthcare through cutting-edge research and development.
MESOX has just won the National Start-Up Award from Medilink UK, building upon the earlier regional win in the Midlands from Medilink Midlands in May this year. The judges highlighted two compelling reasons for their choice: MESOX's work to develop advanced carrier technology with a mission to transform the development of pharmaceuticals, enhance bioavailability, and [...]
MESOX and EuroAPI, a leading CDMO, are partnering to accelerate the development and manufacture of innovative drug delivery carriers. Our collaboration focuses on scaling up MESOX's pioneering nanopore carrier technology, leveraging advanced thermodynamic models and full GMP demonstrator trials. By combining MESOX's expertise in nanopore carrier drug delivery with EuroAPI's established scale-up and modeling capabilities, [...]
MESOX, a pioneering pharmaceutical company, has been awarded the prestigious Start-Up Award at the Medilink Midlands Business Awards 2024. This recognition celebrates MESOX's outstanding achievements in life sciences, particularly its crucial work in transforming pharmaceutical formulation through its game-changing carrier technologies. This award not only highlights MESOX's innovative approach to drug delivery but also underscores [...]
MESOX has been selected as a key participant in the UK government's Reducing Drug Deaths Innovation Challenge Phase 1 SBRI programme. Its innovative RescuePatch project, a groundbreaking transdermal patch designed to combat fatal drug overdoses, has been recognized as a standout among the 11 selected projects. RescuePatch is a unique, controlled-release combination patch that delivers [...]
MESOX has been prominently featured in the International Biopharmaceutical Industry journal. The article, titled "Are We Ready to Formulate the Next Generation of Small Targeted Therapeutics?", highlights the company's revolutionary MesoPAC carrier as a key solution for the unique challenges presented by emerging drug modalities like PROTACs. The article emphasizes the growing importance of overcoming [...]
Your Content Goes Here We're a Finalist! In June 2022, we learnt that MESOX was shortlisted as a Finalist at the RSC’s Emerging Technologies Competition under its Health Category. This is the 10th year for this competition and we are delighted to receive the news at this important time in [...]
Your Content Goes Here In May 2022, MESOX participated in the activities of the LSX World Congress in London. The meeting brought together executives and leaders from Biotech, Healthtech and Medtech companies to discuss the latest developments in life sciences and partnership opportunities. At the event, our team had the opportunity to [...]
© Copyright - 2024 | All Rights Reserved
